Srivastava_2019_Bioorg.Med.Chem_27_3650

Reference

Title : Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, beta-amyloid aggregation and oxidative stress to treat Alzheimer's disease - Srivastava_2019_Bioorg.Med.Chem_27_3650
Author(s) : Srivastava P , Tripathi PN , Sharma P , Shrivastava SK
Ref : Bioorganic & Medicinal Chemistry , 27 :3650 , 2019
Abstract :

Novel hybrids N-(4-phenoxybenzyl)aniline were designed, synthesized, and evaluated for their potential AChE inhibitory activity along with antioxidant potential. The inhibitory potential (IC50) of synthesized analogs was evaluated against human cholinesterases (hAChE and hBChE) using Ellman's method. Among all the tested compounds, 42 with trimethoxybenzene substituent showed maximum hAChE inhibition with the competitive type of enzyme inhibition (IC50=1.32microM; Ki=0.879microM). Further, parallel artificial membrane permeation assay (PAMPA-BBB) showed favorable BBB permeability by most of the synthesized compounds. Meanwhile, compound 42 also inhibited AChE-induced Abeta aggregation (39.5-66.9%) in thioflavin T assay. The in vivo behavioral studies showed dose-dependent improvement in learning and memory by compound 42. The ex vivo studies also affirmed the significant AChE inhibition and antioxidant potential of compound 42 in brain homogenates.

PubMedSearch : Srivastava_2019_Bioorg.Med.Chem_27_3650
PubMedID: 31288978

Related information

Citations formats

Srivastava P, Tripathi PN, Sharma P, Shrivastava SK (2019)
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, beta-amyloid aggregation and oxidative stress to treat Alzheimer's disease
Bioorganic & Medicinal Chemistry 27 :3650

Srivastava P, Tripathi PN, Sharma P, Shrivastava SK (2019)
Bioorganic & Medicinal Chemistry 27 :3650